Skip to main content
Equibles

4547 · KISSEI PHARMACEUTICAL CO.,LTD. · Financials

Use 4547 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4547.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
3,830 JPY +60 (+1.59%) At close · Nov 12
Rebalance outlook locked
Market Cap
159.86B JPY
Shares
41.74M
Volume · Nov 12 71.2K Avg daily vol (3M) 73.92K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
97.41B +10.3%
FY2026 Revenue FY2022–FY2026
Net Income
13.78B +15.2%
FY2026 Net Income FY2022–FY2026
Gross Margin
47.04% -2.8pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
-3% -9.5pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
-1.49B -122.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 97.41B 88.33B 75.58B 67.49B 65.38B
JPY 51.59B 44.27B 38.24B 35.12B 34.14B
JPY 45.82B 44.07B 37.34B 32.37B 31.24B
JPY -2.93B 5.77B 4.02B -1.13B -1.4B
JPY 16.89B 15.61B 14.45B 13.68B 16.51B
JPY 2.93B 3.63B 3.16B 3.05B 3.48B
JPY 13.78B 11.96B 11.16B 10.53B 12.92B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 18.04B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.